35873-49-5 Usage
Description
8-Cyclopentyl-1,3-dimethylxanthine is a selective A1 adenosine receptor antagonist with high binding affinity for the A1 receptor in rat brain membranes. It is a synthetic xanthine derivative that has potential applications in various fields due to its unique chemical structure and receptor binding properties.
Uses
Used in Pharmaceutical Industry:
8-Cyclopentyl-1,3-dimethylxanthine is used as a selective A1 adenosine receptor antagonist for its potential therapeutic applications in treating various disorders related to adenosine receptor activity. Its high binding affinity for the A1 receptor (Ki = 10.9 nM) makes it a promising candidate for the development of drugs targeting this receptor.
Used in Neurological Research:
8-Cyclopentyl-1,3-dimethylxanthine is used as a research tool in the study of adenosine receptors and their role in neurological processes. Its selective antagonism of the A1 receptor allows researchers to investigate the specific functions and interactions of this receptor in the brain, which can contribute to a better understanding of neurological diseases and the development of targeted therapies.
Used in Drug Discovery and Development:
8-Cyclopentyl-1,3-dimethylxanthine serves as a lead compound in the discovery and development of new drugs targeting adenosine receptors. Its unique chemical structure and receptor binding properties can be further optimized and modified to create more potent and selective antagonists or agonists, potentially leading to the development of novel therapeutic agents for various conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 35873-49-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,8,7 and 3 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 35873-49:
(7*3)+(6*5)+(5*8)+(4*7)+(3*3)+(2*4)+(1*9)=145
145 % 10 = 5
So 35873-49-5 is a valid CAS Registry Number.
InChI:InChI=1/C12H16N4O2/c1-15-10-8(11(17)16(2)12(15)18)13-9(14-10)7-5-3-4-6-7/h7H,3-6H2,1-2H3,(H,13,14)
35873-49-5Relevant articles and documents
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
Suzuki,Shimada,Mizumoto,Karasawa,Kubo,Nonaka,Ishii,Kawakita
, p. 3066 - 3075 (2007/10/02)
Diuretic activities of xanthine or nonxanthine adenosine antagonists and their ameliorative effects against glycerol-induced acute renal failure in rats were investigated in order to clarify the physiological and pathological function of adenosine receptors in the kidney. Diuretic and natriuretic activities of a variety of adenosine antagonists clarified systematically for the first time that the blockade of A1 receptors is more important than that of A2 receptors in sodium and water excretion and support the hypothesis that endogenous intrarenal levels of adenosine directly enhance tubular sodium readsorption. Studies of structure-activity relationships of 8-substituted xanthines in the acute renal failure demonstrated that the activation of adenosine A1 receptor was an important factor in developing such a renal failure. A series of 8-(3-noradamantyl)xanthines exhibited the extremely potent diuretic and natriuretic activities (24; 2.5 micrograms/kg, po, the ratio of urinary excretion value in treated rats to urinary excretion value in control rats = 1.69, the ratio of Na+/K+ in treated rats to Na+/K+ in control rats = 1.76) and potent ameliorative effects against glycerol-induced acute renal failure (24; 10 micrograms/kg, ip, 55% inhibition). From our detailed studies of structure-activity relationships, we can speculate that some tissue differences of the adenosine A1 receptor might exist between kidney and brain and sites of action for adenosine antagonists could be different between two renal pharmacological assays. 1,3-Dipropyl-8-(3-noradamantyl)xanthine, KW-3902 (24), was chosen for further studies and is under development as a drug for treating the acute renal failure.
